Home-based HIV care strategy is as effective as clinic-based strategy in Uganda

November 23, 2009

Home-based care results in similar outcomes as clinic-based strategies for HIV patients in Africa, concludes an Article published Online First (www.thelancet.com) and in an upcoming edition of The Lancet. The Article is written by Dr Shabbar Jaffar, London School of Hygiene and Tropical Medicine, UK, and colleagues.

Antiretroviral drug therapy has been scaled up rapidly in Africa, and is now given to more than 2 million people. A global commitment has been made to provide universal coverage, but another 5 million people, mostly living in rural and semiurban areas, are estimated to need such treatment. Achievement of high coverage in these populations will be a challenge. Two major barriers to increasing coverage exist--a severe shortage of clinically qualified staff, which has reached crisis point in most of Africa, and difficulty for patients in accessing clinics because of high costs and poor availability of transport and low cash incomes. In this study, the authors assessed whether home-based HIV care was as effective as was facility-based care. The team worked with TASO--a non-governmental organisation in Uganda which offers a range of services to HIV patients.

In this cluster-randomised trial in Jinja, Uganda, 44 geographical areas in nine regions were defined according to the ratio of urban and rural participants and distance from the nearest clinic. These areas were randomised to home-based or facility based care. For the clinic-treated patients, conditions at the clinic were representative of those nationally, with similar numbers of nurses, laboratory and pharmacy staff. For the home-based group, trained field officers travelling on motorcycles visited patients at home every month to deliver drugs, monitor participants with a checklist that included signs and symptoms of drug toxicity or disease progresion, and provide adherence support.

All patients were in the later stages of HIV (late WHO stage III or stage IV, or CD4-cell counts fewer than 200 cells per μL of blood), and had started antiretroviral therapy between Feb 2005 and December 2006. Follow-up continued until January 2009. The primary endpoint was virilogical failure, defined as HIV RNA of 500 copies per mL after 6 months of treatment.

A total of 859 patients were randomly assigned to home and 594 to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care. The rates of virologicial failure per 100 person-years were 8.19 for home and 8.67, for facility care, meaning the two treatment modes were statistically equivalent.

The authors conclude: "We have shown that home-based HIV care with antiretroviral therapy is an effective strategy, which relies less on clinical staff and hospital services than does facility-based care and provides large savings for patients. Such community-based strategies could enable improved and equitable access to HIV treatment--especially in areas in which clinical infrastructure is scarce and patient access to clinic-based care is poor."

In an accompanying Comment, Dr Eline L Korenromp and Dr Kirsi M Viisainen, Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland, say: "TASO's package of home-based care is especially appealing because it combines ART with free voluntary HIV counselling and testing in the home for household members of patients. The twice-lower cost to patients on ART probably contributed to relatively good adherence in the home-based clusters, which may become even more crucial as patients accumulate years of treatment."

They conclude: "The current situation in which demand for scaling up ART in many high-burden countries meets or exceeds globally available HIV and health funds is unprecedented. Programme evaluations, including both health outcomes and cost, are more important than ever to plan and budget for optimum sustainable packages of treatment and prevention services."
-end-
Dr Shabbar Jaffar, London School of Hygiene and Tropical Medicine, UK. T) +44 (0) 20 7927 2418 / +44 (0) 7900 924 473 E) shabbar.jaffar@lshtm.ac.uk

Dr Eline L Korenromp, Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland. T) +41 58 791 1732 E) eline.korenromp@theglobalfund.org

Andrew Hurst.senior media specialist at the Global Fund to fight AIDS, Tuberculosis and Malaria. T) +41 58 791 1672 E) andrew.hurst@theglobalfund.org

For full Article and Comment, see: http://press.thelancet.com/hivcare.pdf

Lancet

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.